The pathogenesis and therapeutic option of encapsulating peritoneal sclerosis

International Journal of Artificial Organs

Volumn 28, Issue 2, 2005, Pages 150-155

  Kawanishi, Hideki ^a  

^a TSUCHIYA GENERAL HOSPITAL   (Japan)

Author keywords

Encapsulating peritoneal sclerosis; EPS; Peritoneal deterioration; Peritoneal dialysis; Surgical option

Indexed keywords

DETERIORATION; DIALYSIS;

BOWEL OBSTRUCTION; ENCAPSULATING PERITONEAL SCLEROSE; GASTROINTESTINAL SYMPTOMS; PERITONEAL DETERIORATION; PERITONEAL DIALYSIS; SURGICAL OPTION;

PATIENT TREATMENT;

GLUCOSE DEGRADATION PRODUCT; PERITONEAL DIALYSIS FLUID; STEROID;

ABDOMINAL SURGERY; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFICACY; FATALITY; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; INTESTINE OBSTRUCTION; JAPAN; LAPAROTOMY; LONG TERM CARE; MEDICAL DECISION MAKING; MORTALITY; PATHOGENESIS; PATIENT MONITORING; PERITONEAL DIALYSIS; PERITONEUM; REVIEW; RISK ASSESSMENT; SCLEROSIS; STEROID THERAPY; TOTAL PARENTERAL NUTRITION; TREATMENT PLANNING;

EID: 16844375443     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880502800211     Document Type: Review

References (39)

1. Kawaguchi Y, Kawanishi H, Mujais S, et al. Encapsulating peritoneal sclerosis: Definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000; 20 (suppl 4): S43-55.
2. Gandhi VC, Humayan HM, Ing TS, et al. Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. Arch Intern Med 1980; 140: 1201-3.
3. Denis J, Paineau J, Potel G, et al. Continuous ambulatory peritoneal dialysis. Ann Intern Med 1980; 93: 508.
4. Slingeneyer A. Preliminary report on a cooperative international study on sclerosing encapsulating peritonitis. Contrib Nephrol 1987; 57: 239-47.
5. Oules R, Challah S, Brunner FP. Case-control study to determine the cause of sclerosing peritoneal disease. Nephrol Dial Transplant 1988; 3: 66-9.
6. Rigby RJ, Hawley CM, Sclerosing peritonitis: The experience in Australia. Nephrol Dial Transplant 1998; 13: 154-9.
7. Nomoto Y, Kawaguchi Y, Kubo H, et al. Sclerosing encapsulating peritonitis in patients undergoing continuous peritoneal dialysis. A report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Dis 1996; 28: 420-7
8. Kawanishi H, Kawaguchi Y, Fukui H, et al. Encapsulating peritoneal sclerosis in Japan; prospective multicenter survey. Am J Kidney Dis 2004; 44: 729-37.
9. Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992; 12: 14-27.
10. Bentley PG, Higgs DR. Peritoneal tuberculosis with ureteric obstruction, mimicking retroperitoneal fibrosis. Br J Urol 1976; 48: 170.
11. Sugarbaker PH, Landy D, Jaffe G, Pascal R. Histologic changes induced by intraperitoneal chemotherapy with 5-fluorouracil and mitomycin C in patients with peritoneal carcinomatosis from cystadenocarcinoma of the colon or appendix. Cancer 1990; 65: 1495-501.
12. Markman M, Cleary S, Howell SB, Lucas WE. Complications of extensive adhesion formation after intraperitoneal chemotherapy. Surg Gynecol Obstet 1986; 162: 445-8.
13. Mackow RC, Winchester JF, Argy WP, Andrews PM, Fields PA, Bates S, et al. Sclerosing encapsulating peritonitis in rats: An experimental study with intraperitoneal antiseptics. Contrib Nephrol 1987; 57: 213-8.
14. Lo WK, Chan KT, Leung AC, Pang SW, Tse CY. Sclerosing peritonitis complicating continuous ambulatory peritoneal dialysis with the use of chlorhexidine in alcohol. Adv Perit Dial 1990; 6: 79-84.
15. Brown P, Baddeley H, Read AE, Davies JD, McGarry J. Sclerosing peritonitis, an unusual reaction to a beta-adrenergic-blocking drug (practolol). Lancet 1974; 2: 1477-81.
16. Thompson RP, Jackson BT. Sclerosing peritonitis due to practolol. Br Med J 1977; 1: 1393-4.
17. Eltringham WK, Espiner HJ, Windsor CW, Griffiths DA, Davies JD, Baddeley H, et al. Sclerosing peritonitis due to practolol: A report on 9 cases and their surgical management. Br J Surg 1977; 64: 229-35.
18. Hall DR, Morrison JB, Edwards FR. Pleural fibrosis after practolol therapy. Thorax 1978; 33: 822-4.
19. Dobbie JW, Lloyd JK. Mesothelium secretes lamellar bodies in a similar manner to type II pneumocyte secretion of surfactant. Perit Dial Int 1989; 9: 215-9.
20. Baxter-Smith DC, Monypenny IJ, Dorricott NJ. Sclerosing peritonitis in patient on timolol (Letter). Lancet 1978; 2: 149.
21. Clark CV, Terris R. Sclerosing peritonitis associated with metoprolol (Letter). Lancet 1983; 1: 937.
22. McLaughlin K, Butt G, Madi A, McMillan M, Mactier R. Sclerosing peritonitis occurring in a hemodialysis patients. Am J Kidney Dis 1996; 27: 729-32.
23. Yanagi H, Kusunoki M, Yamamura T. Possible development of idiopathic sclerosing encapsulating peritonitis. Hepatogastroenterology 1999; 46: 353-6.
24. Frigerio L, Taccagni GL, Mariani A, Mangili G, Ferrari A. Idiopathic sclerosing peritonitis associated with florid mesothelial hyperplasia, ovarian fibromatosis, and endometriosis: A new disorder of abdominal mass. Am J Obstet Gynecol 1997; 176: 721-2.
25. Kawanishi H, Watanabe H, Moriishi M, Tsuchiya S. Encapsulating peritoneal sclerosis-like findings in a hemodialysis patient without a history of peritoneal dialysis. Adv Perit Dial 2003; 19: 176-9.
26. Williams JD, Craig KJ, Topley N, et al. Peritoneal Biopsy Study Group. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-9.
27. De Vriese AS, Tilton RG, Stephan CC, et al. Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. J Am Soc Nephrol 2001; 12: 1734-41.
28. Numata M, Nakayama M, Nimura S, et al. Association between an increased surface area of peritoneal microvessels and a high peritoneal solute transport rate. Perit Dial Int 2003; 23: 116-22.
29. Williams JD, Topley N, Craig KJ, et al. The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408-18.
30. Sjoland JA, Smith Pedersen R, Jespersen J, et al. Intraperitoneal heparin reduces peritoneal permeability and increases ultrafiltration in peritoneal dialysis patients. Nephrol Dial Transplant 2004; 19: 1264-8.
31. Mizuiri S, Miyata S, Sakai K, et al. Effect of intraperitoneal administration of heparin on advanced glycation end-products in CAPD. Perit Dial Int 1999; 19: 361-5.
32. Nakayama M, Yamamoto H, Ikeda M, et al. Risk factors and preventive measures for encapsulating peritoneal sclerosis Jikei experience 2002. Adv Perit Dial 2002; 18: 144-8.
33. Moriishi M, Kawanishi H, Kawai T, et al. Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis. Adv Perit Dial 2002; 18: 149-53.
34. Junor BJR, McMillan MA. Immunosuppression in sclerosing peritonitis. Adv Perit Dial 1993; 9: 187-9.
35. Mori Y, Tatsuo S, Sutoh H, Toriyama T, Kawahara H, Hotta N. A case of a dialysis patients with sclerosing peritonitis successfully treated with corticosteroid therapy alone. Am J Kidney Dis 1997; 30: 275-8.
36. Smith L, Collins J, Morris M, Teele R. Sclerosing encapsulating peritonitis associated with continuous ambulatory peritoneal dialysis: Surgical management. Am J Kidney Dis 1997; 29: 456-60.
37. Lubbert E, Zimmering M, Kirchmair F, Filler G, Tennstedt C, Rudolph B, et al. Successful surgical treatment of sclerosing peritonitis persisting after renal transplantation (Letter). Pediatr Nephrol 1998; 12: 525-6.
38. Kawanishi H, Harada Y, Noriyuki T, et al. Treatment options for encapsulating peritoneal sclerosis based on progressive stage. Adv Perit Dial 2001; 17, 200-4.
39. Kawanishi H, Watanabe H, Moriishi M, Tsuchiya S. Successful surgical management of encapsulating peritoneal sclerosis. Perit Dial Int 2005; 25 (suppl 4) (in press).